Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that ha… Read more
Aileron Therapeutics Inc (ALRN) - Net Assets
Latest net assets as of September 2024: $50.23 Million USD
Based on the latest financial reports, Aileron Therapeutics Inc (ALRN) has net assets worth $50.23 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.22 Million) and total liabilities ($53.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $50.23 Million |
| % of Total Assets | 48.19% |
| Annual Growth Rate | -8.66% |
| 5-Year Change | -57.08% |
| 10-Year Change | N/A |
| Growth Volatility | 271.14 |
Aileron Therapeutics Inc - Net Assets Trend (2014–2023)
This chart illustrates how Aileron Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aileron Therapeutics Inc (2014–2023)
The table below shows the annual net assets of Aileron Therapeutics Inc from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $6.89 Million | -63.02% |
| 2022-12-31 | $18.62 Million | -57.58% |
| 2021-12-31 | $43.90 Million | +260.99% |
| 2020-12-31 | $12.16 Million | -24.21% |
| 2019-12-31 | $16.05 Million | -18.12% |
| 2018-12-31 | $19.60 Million | -58.99% |
| 2017-12-31 | $47.80 Million | +142.75% |
| 2016-12-31 | $-111.81 Million | -18.54% |
| 2015-12-31 | $-94.32 Million | -705.93% |
| 2014-12-31 | $15.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aileron Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20517600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.00K | 1.32% |
| Other Comprehensive Income | $-63.00K | -0.91% |
| Other Components | $295.38 Million | 4288.89% |
| Total Equity | $6.89 Million | 100.00% |
Aileron Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aileron Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kjell Group AB
ST:KJELL
|
$40.99 Million |
|
AVE S.A.
AT:AVE
|
$40.99 Million |
|
OPAL Fuels Inc
NASDAQ:OPAL
|
$40.99 Million |
|
Northfield Capital Corporation
V:NFD-A
|
$41.00 Million |
|
Mercator Medical S.A.
WAR:MRC
|
$40.98 Million |
|
Goodness Growth Holdings Inc
OTCQX:GDNSF
|
$40.98 Million |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
$40.97 Million |
|
Uniquest
KO:077500
|
$40.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aileron Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 18,623,000 to 6,887,000, a change of -11,736,000 (-63.0%).
- Net loss of 15,732,000 reduced equity.
- Other comprehensive income decreased equity by 15,000.
- Other factors increased equity by 4,011,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.73 Million | -228.43% |
| Other Comprehensive Income | $-15.00K | -0.22% |
| Other Changes | $4.01 Million | +58.24% |
| Total Change | $- | -63.02% |
Book Value vs Market Value Analysis
This analysis compares Aileron Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-172.83 | $2.11 | x |
| 2016-12-31 | $-204.88 | $2.11 | x |
| 2017-12-31 | $128.43 | $2.11 | x |
| 2018-12-31 | $26.60 | $2.11 | x |
| 2019-12-31 | $13.08 | $2.11 | x |
| 2020-12-31 | $6.98 | $2.11 | x |
| 2021-12-31 | $9.89 | $2.11 | x |
| 2022-12-31 | $4.10 | $2.11 | x |
| 2023-12-31 | $1.50 | $2.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aileron Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -228.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 15.39x
- Recent ROE (-228.43%) is below the historical average (-99.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.82 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.45 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.94 Million |
| 2017 | -47.29% | 0.00% | 0.00x | 1.10x | $-27.38 Million |
| 2018 | -160.95% | 0.00% | 0.00x | 1.55x | $-33.51 Million |
| 2019 | -179.35% | 0.00% | 0.00x | 1.65x | $-30.39 Million |
| 2020 | -179.39% | 0.00% | 0.00x | 1.34x | $-23.03 Million |
| 2021 | -58.68% | 0.00% | 0.00x | 1.10x | $-30.15 Million |
| 2022 | -145.04% | 0.00% | 0.00x | 1.18x | $-28.87 Million |
| 2023 | -228.43% | 0.00% | 0.00x | 15.39x | $-16.42 Million |
Industry Comparison
This section compares Aileron Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aileron Therapeutics Inc (ALRN) | $50.23 Million | 0.00% | 1.07x | $40.98 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |